A 5 Day Course of Fludarabine and Cytarabine Followed by Full Intensity Allogeneic Stem Cell Transplantation (FA5-Bucy) in Treating Patients With High-risk, Recurrent or Refractory Acute Leukemia and Advanced Myelodysplastic Syndrome

Trial Profile

A 5 Day Course of Fludarabine and Cytarabine Followed by Full Intensity Allogeneic Stem Cell Transplantation (FA5-Bucy) in Treating Patients With High-risk, Recurrent or Refractory Acute Leukemia and Advanced Myelodysplastic Syndrome

Recruiting
Phase of Trial: Phase II

Latest Information Update: 06 Dec 2016

At a glance

  • Drugs Cytarabine (Primary) ; Fludarabine (Primary) ; Busulfan; Cyclophosphamide
  • Indications Leukaemia; Myelodysplastic syndromes
  • Focus Therapeutic Use
  • Acronyms FA5-Bucy
  • Most Recent Events

    • 06 Dec 2016 Results (n=64) assessing outcomes of Haploidentical hematopoietic stem cell transplantation, presented at the 58th Annual Meeting and Exposition of the American Society of Hematology
    • 08 Jan 2015 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top